Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patent

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing public interest and high prices. Natco is required to maintain detailed financial records and may owe damages if Roche ultimately wins the case.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zsjncES
via IFTTT